| First Author | Mor DE | Year | 2017 |
| Journal | Nat Neurosci | Volume | 20 |
| Issue | 11 | Pages | 1560-1568 |
| PubMed ID | 28920936 | Mgi Jnum | J:258033 |
| Mgi Id | MGI:6116552 | Doi | 10.1038/nn.4641 |
| Citation | Mor DE, et al. (2017) Dopamine induces soluble alpha-synuclein oligomers and nigrostriatal degeneration. Nat Neurosci 20(11):1560-1568 |
| abstractText | Parkinson''s disease (PD) is defined by the loss of dopaminergic neurons in the substantia nigra and the formation of Lewy body inclusions containing aggregated alpha-synuclein. Efforts to explain dopamine neuron vulnerability are hindered by the lack of dopaminergic cell death in alpha-synuclein transgenic mice. To address this, we manipulated both dopamine levels and alpha-synuclein expression. Nigrally targeted expression of mutant tyrosine hydroxylase with enhanced catalytic activity increased dopamine levels without damaging neurons in non-transgenic mice. In contrast, raising dopamine levels in mice expressing human A53T mutant alpha-synuclein induced progressive nigrostriatal degeneration and reduced locomotion. Dopamine elevation in A53T mice increased levels of potentially toxic alpha-synuclein oligomers, resulting in conformationally and functionally modified species. Moreover, in genetically tractable Caenorhabditis elegans models, expression of alpha-synuclein mutated at the site of interaction with dopamine prevented dopamine-induced toxicity. These data suggest that a unique mechanism links two cardinal features of PD: dopaminergic cell death and alpha-synuclein aggregation. |
